SCHEMBL1482888

SCHEMBL1482888

COc1cc(Cl)ccc1-c1nc2ccccc2n1CC1CCCCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.52
KDM4E B2RXH2 3/20 0.47
NPSR1 Q6W5P4 2/20 0.47
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47
PRKACA P17612 2/20 0.45
RPS6KB1 P23443 2/20 0.45
GSK3B P49841 2/20 0.45
ROCK1 Q13464 2/20 0.45
ALDH1A1 P00352 2/20 0.43
HSD17B10 Q99714 2/20 0.43
CRHR1 P34998 1/20 0.43
KCNH2 Q12809 1/20 0.42
PDE6D O43924 1/20 0.42
TP53 P04637 2/20 0.42
BRD4 O60885 5/20 0.41
BAZ2A Q9UIF9 2/20 0.41
NPC1 O15118 1/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1482662 0.86 NR1H4 (0.51) ALOX5CRHR1KCNH2HPGD
SCHEMBL1482462 0.85 ALOX5 (0.53) ALOX5KDM4ENPSR1LMNAHTT
SCHEMBL1482722 0.84 NR1H4 (0.49) ALOX5CRHR1KCNH2HPGD
SCHEMBL1482155 0.84 ALOX5 (0.52) ALOX5KDM4ENPSR1PRKACARPS6KB1
SCHEMBL1577202 0.81 ALOX5 (0.43) ALOX5CRHR1KCNH2BRD4HPGD
SCHEMBL1577251 0.80 CRHR1 (0.41) ALOX5CRHR1KCNH2BRD4HPGD
SCHEMBL1482337 0.78 GLP1R (0.40) ALOX5NPSR1PRKACARPS6KB1GSK3B
SCHEMBL25312966 0.77 BRD4 (0.48) KDM4ENPSR1LMNAHTTPRKACA
SCHEMBL30472189 0.77 BRD4 (0.48) KDM4ENPSR1LMNAHTTPRKACA
SCHEMBL1577839 0.77 ALOX5 (0.45) ALOX5KDM4ENPSR1HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309581-B2 Benzimidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2012-11-13 US disclosed
EP-2483247-A1 NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. Hoffmann-La Roche AG (CH) 2012-08-08 EP disclosed
WO-2011039130-A1 NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-04-07 WO disclosed
US-20110077273-A1 NEW BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077273-A1 NEW BENZIMIDAZOLE DERIVATIVES BRI3BP, CYP3A4, RB1 ALOX5 3919/4885KDM4E 1791/4885NPSR1 1227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.